- Exchange: Frankfurt
- Sector: Consumer, Non-cyclical
- Industry: Biotechnology
- Sub-Industry: Medical-Biomedical/Gene
Aastrom Biosciences Inc
+ Add to WatchlistATQN:GR
0.470 EUR 0.022 4.47%As of 02:09:14 ET on 05/17/2013.
Snapshot for Aastrom Biosciences Inc (ATQN)
| Open: | 0.427 | Day's Range: | 0.426 - 0.470 | Volume: | 0 |
|---|---|---|---|---|---|
| Previous Close: | 0.492 | 52wk Range: | 0.364 - 1.841 | 1-Yr Rtn: | -70.10% |
Key Statistics for ATQN
| Current P/E Ratio (ttm) | - |
|---|---|
| Estimated P/E(12/2013) | - |
| Relative P/E vs. DAX | - |
| Earnings Per Share (USD) (ttm) | - |
| Est. EPS (USD) (12/2013) | -0.5590 |
| Est. PEG Ratio | - |
| Market Cap (M EUR) | 0.00 |
| Shares Outstanding (M) | 0.00 |
| 30 Day Average Volume | 585 |
| Price/Book (mrq) | - |
| Price/Sale (ttm) | - |
| Dividend Indicated Gross Yield | -% |
| Cash Dividend | - |
| Last Dividend | |
| 5 Year Dividend Growth | - |
| Next Earnings Announcement | 08/07/2013 |
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for ATQN
Company Profile & Key Executives for ATQN
Aastrom Biosciences, Inc. develops autologous stem/progenitor cell products for the repair/regeneration of tissues based on Tissue Repair Cell (TRC) adult stem cell technology. The Company's products contain bone marrow stem and progenitor cells that are produced from cells originating from the patient.
| Dominick C Colangelo "Nick"President/CEO | Daniel Orlando "Dan"Chief Business Officer |
| Ronnda L BartelChief Scientific Officer | Brian D GibsonVP:Finance/Chief Acctg Ofcr/Secy |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
-
ATQN News
-
Industry News
Advertisement
- 1
- 2
- 3
- 4
- 5
Advertisement
Sponsored Links
Advertisements
Rate this Page